Neuropharmacology researchers are scientists who study how drugs affect the nervous system, aiming to understand and develop treatments for neurological and psychiatric disorders. Their work focuses on the interaction between chemicals and neural pathways to uncover how various substances influence brain function, behavior, and cognition. These researchers explore the mechanisms of action of neurotransmitters, receptors, and ion channels, and investigate how different compounds can modulate these targets to alleviate symptoms or alter disease progression. Neuropharmacology bridges multiple disciplines including biology, chemistry, and medicine, making it a critical field for advancing treatments for conditions such as depression, epilepsy, Parkinson’s disease, Alzheimer’s, and chronic pain.
Neuropharmacology researchers conduct experiments using cell cultures, animal models, and clinical trials to test new drugs and understand their effects on the nervous system. Their discoveries often lead to the development of safer and more effective medications, improving the quality of life for patients with complex neurological diseases. Collaboration with neurologists, psychiatrists, and pharmaceutical companies is essential to translate basic research into clinical therapies. Advances in neuropharmacology have contributed to the creation of targeted treatments that minimize side effects and enhance efficacy. As brain disorders continue to pose significant challenges, neuropharmacology researchers play a vital role in unlocking new therapeutic possibilities and shaping the future of neurological medicine.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States